Lacrat

Ticagrelor, the active ingredient in Lacrat, is a P2Y12 receptor antagonist presented as an oral tablet for oral use. It treats acute coronary syndrome, myocardial infarction, and helps prevent thrombotic cardiovascular events in adult patients.\n\nGNH India supplies Lacrat as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacrat (ticagrelor) acts on platelet aggregation pathways to reduce thrombotic risk in cardiovascular disease.\n\nAcute coronary syndrome: lowers the incidence of cardiovascular death, myocardial infarction and stroke.\nMyocardial infarction: prevents recurrent ischemic events after an acute event.\nPrevention of thrombotic cardiovascular events: reduces clot formation in patients at high risk of arterial thrombosis.

Adverse reactions may range from mild to severe and should be monitored during therapy.\n\nCommon Side Effects:\n- Dyspnea: shortness of breath, often transient.\n- Headache: mild to moderate intensity.\n- Nausea: occasional gastrointestinal upset.\n- Bleeding: minor bruising or gum bleeding.\n- Dizziness: light‑headed sensations.\n- Diarrhea: loose stools in some patients.\n\nSerious or Rare Side Effects:\n- Severe bleeding: intracranial or gastrointestinal hemorrhage.\n- Hypersensitivity reactions: rash, angioedema, anaphylaxis.\n- Hepatic injury: elevated liver enzymes or hepatitis.\n- Thrombocytopenia: marked reduction in platelet count.

Before initiating Lacrat, clinicians should evaluate patient‑specific risk factors and monitor therapy.\n\nAssess bleeding risk: review history of hemorrhage or anticoagulant use.\nMonitor liver function: periodic tests for hepatic safety.\nAdjust dose in renal impairment: consider reduced dosing for severe renal dysfunction.\nAvoid use in active pathological bleeding: contraindicated in ongoing hemorrhage.\nReview concomitant anticoagulants: increased bleeding potential with warfarin or DOACs.\nStore at ambient temperature: keep in the original pack, protect from moisture.

Ticagrelor may interact with several drug classes, requiring careful management.\n\nMajor Interactions (Avoid):\n- Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ticagrelor exposure.\n- Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy.\n- Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk.\n- Non‑steroidal anti‑inflammatory drugs (NSAIDs): additive bleeding potential.\n\nModerate Interactions (Monitor Closely):\n- Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may modestly raise levels.\n- Moderate CYP3A4 inducers (e.g., phenytoin, phenobarbital): may modestly lower levels.\n- Selective serotonin reuptake inhibitors (SSRIs) or SNRIs: increased bleeding tendency.